Skip to content
OpenCapital
Get started

Rigel Pharmaceuticals RIGL fostamatinib — Revenue recognized

Similar metrics at other companies

Organon logo
OGNFosamax — Revenue
$29M-12.1%
XOMA Corporation logo
XOMATovorafenib — Income Not From Contract With Customer Cost Recovery Method
$2.77M-49.9%
Biogen logo
BIIBFumarate — Total Revenue
$288.5M-16.4%
Biogen logo
BIIBFAMPYRA — Total Revenue
$0-100%
Catalyst Pharmaceutical logo
CPRXFirdapse — Revenue
$98.86M+18.1%
Organon logo
OGNFollistim AQ — Revenue
$61M-11.6%

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K—
Free cash flow-$22.0M—

Valuation

See full
Market cap$684.39M+102%
Enterprise value$728.29M+148%
P/E1.9×-7.2×
P/S2.3×+0.6×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%—

Returns & leverage

See full
Return on equity174.1%—
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept rigl:CollaborativeArrangementRevenueRecognized.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's fostamatinib — revenue recognized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rigel Pharmaceuticals's fostamatinib — revenue recognized?
Rigel Pharmaceuticals (RIGL) reported fostamatinib — revenue recognized of $300K in Q1 2026.
How has Rigel Pharmaceuticals's fostamatinib — revenue recognized changed year-over-year?
Rigel Pharmaceuticals's fostamatinib — revenue recognized decreased by 25.0% year-over-year, from $400K to $300K.
What is the long-term trend for Rigel Pharmaceuticals's fostamatinib — revenue recognized?
Over 2 years (2021 to 2023), Rigel Pharmaceuticals's fostamatinib — revenue recognized has grown at a -76.1% compound annual growth rate (CAGR), from $10.5M to $600K.
What does fostamatinib — revenue recognized mean?
The total revenue earned from the sale or licensing of the fostamatinib product during the reporting period. This metric reflects the successful commercialization or milestone achievement associated with the drug. It serves as a primary indicator of the product's market adoption and financial contribution to the company.